Pengxing He

582 total citations
21 papers, 444 citations indexed

About

Pengxing He is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Pengxing He has authored 21 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Pengxing He's work include Epigenetics and DNA Methylation (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Pengxing He is often cited by papers focused on Epigenetics and DNA Methylation (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Pengxing He collaborates with scholars based in China, New Zealand and United States. Pengxing He's co-authors include Jian Ding, Hong‐Min Liu, Bin Yu, Yi‐Chao Zheng, Yi Chen, Jie Zhang, Fengyu Qi, Wen Zhao, Junwei Wang and Xiao Chu and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and ACS Applied Materials & Interfaces.

In The Last Decade

Pengxing He

20 papers receiving 438 citations

Peers

Countries citing papers authored by Pengxing He

Since Specialization

Citations

This map shows the geographic impact of Pengxing He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pengxing He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pengxing He more than expected).

Fields of papers citing papers by Pengxing He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pengxing He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pengxing He. The network helps show where Pengxing He may publish in the future.

Co-authorship network of co-authors of Pengxing He

This figure shows the co-authorship network connecting the top 25 collaborators of Pengxing He. A scholar is included among the top collaborators of Pengxing He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pengxing He. Pengxing He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure-Based Design of New LSD1/EGFR^L858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers 2025 ·Journal of Medicinal Chemistry ·Jingya Zhang, Pengxing He, Wenwen Wang, (unknown), Han Yang, Zhaoxin Hu, Yihui Song, Junbiao Chang, Bin Yu	4
2	A Helicene‐Based Single‐Molecule Inductor and Capacitor with Frequency‐Dependent Charge‐Transport Pathways 2024 ·Angewandte Chemie International Edition ·Pengxing He, (unknown), Junrui Zhang, (unknown), (unknown), Junyang Liu, Chengshuo Shen, Wenjing Hong, Xunshan Liu	7
3	The combination of SLC7A11 inhibitor and oridonin synergistically inhibits cervical cancer cell growth by decreasing the NADPH/NADP+ ratio 2024 ·Genes & Diseases ·Yajie Liu, (unknown), Pengxing He, (unknown), (unknown), Yu Zhang, (unknown), (unknown), Hong‐Min Liu, (unknown), (unknown), (unknown)	0
4	PIK3IP1: structure, aberration, function, and regulation in diseases 2024 ·European Journal of Pharmacology ·(unknown), Pengxing He, (unknown), (unknown), Ying Liu, (unknown)	2
5	Ferroptosis: Opportunities and Challenges in Cancer 2023 ·Yingjie Jia, Yu Zhang, (unknown), Yang Wang, (unknown), Pengxing He, (unknown)	2
6	Discovery of YS-363 as a highly potent, selective, and orally eﬃcacious EGFR inhibitor 2023 ·Biomedicine & Pharmacotherapy ·Pengxing He, Jing Jing, (unknown), Xuyang Zhang, Yufei Ren, (unknown), Bin Yu, Hong‐Min Liu	4
7	Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors 2023 ·Bioorganic Chemistry ·Pengxing He, (unknown), Qing-Qing Dai, Guo‐Bo Li, Bin Yu, Linlin Chang	11
8	Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC 2023 ·Cell Death and Disease ·Linna Du, Yang Han, Yufei Ren, Yanli Ding, Yichao Xu, Xiaolin Zi, Hong‐Min Liu, Pengxing He	21
9	Effective Approach toward Selective Near-Infrared Dyes: Rational Design, Synthesis, and Characterization of Thieno[3,4-b]thiophene-Based Quinoidal Oligomers 2022 ·ACS Applied Materials & Interfaces ·(unknown), Xinwei Zhang, Pengxing He, (unknown), (unknown), Valerii Sharapov, Xunshan Liu, Luping Yu	2
10	Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell 2022 ·Molecular Biology Reports ·(unknown), Hao Pan, Junwei Wang, Wen Zhao, Hong‐Min Liu, Pengxing He	4
11	Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma 2022 ·Genes & Diseases ·Pengxing He, Linna Du, Hao Pan, Yang Han, Yufei Ren, (unknown), Yanli Ding, Zhao Wen, (unknown), Hong‐Min Liu	5
12	ATRA promotes PD-L1 expression to control gastric cancer immune surveillance 2022 ·European Journal of Pharmacology ·(unknown), Yanli Ding, Jing Jing, (unknown), Xuyang Zhang, Hong‐Min Liu, Pengxing He	6
13	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing 2020 ·Acta Pharmaceutica Sinica B ·Zhiru Wang, (unknown), Ouwen Li, Fengyu Qi, Junwei Wang, (unknown), Pengxing He, Zhenhe Suo, Yi‐Chao Zheng, Hong‐Min Liu	101
14	Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer 2019 ·Life Sciences ·Pengxing He, (unknown), Huan Han, Xuyang Zhang, (unknown), (unknown), Yi‐Chao Zheng, Hong‐Min Liu	22
15	Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor 2019 ·Acta Pharmaceutica Sinica B ·Pengxing He, (unknown), Shuai Wang, Xiaojing Shi, Siqi Feng, (unknown), Xuyang Zhang, (unknown), Bin Yu, Hong‐Min Liu	17
16	G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1 2018 ·Theranostics ·Jie Zhang, Wang Yf, Yanyan Shen, Pengxing He, Jian Ding, Yi Chen	26
17	Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment 2016 ·Current Topics in Medicinal Chemistry ·(unknown), Bin Yu, (unknown), (unknown), Pengxing He, Xiao Chu, Wen Zhao, (unknown)	77
18	Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation 2015 ·Oncotarget ·Jie Zhang, Pengxing He, Yong Xi, Meiyu Geng, Yi Chen, Jian Ding	52
19	G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation 2014 ·Acta Pharmacologica Sinica ·Pengxing He, Jie Zhang, Yongsheng Che, Qiaojun He, Yi Chen, Jian Ding	19
20	G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro 2014 ·Acta Pharmacologica Sinica ·Pengxing He, Yongsheng Che, Qiaojun He, Yi Chen, Jian Ding	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact